Compare BODI & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BODI | MCRB |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | 270 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.4M | 71.0M |
| IPO Year | N/A | 2015 |
| Metric | BODI | MCRB |
|---|---|---|
| Price | $10.13 | $7.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $15.00 | $14.00 |
| AVG Volume (30 Days) | 25.8K | ★ 107.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.76 | $5.31 |
| 52 Week High | $16.87 | $29.98 |
| Indicator | BODI | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 57.98 |
| Support Level | $9.42 | $6.56 |
| Resistance Level | $11.11 | $9.53 |
| Average True Range (ATR) | 0.75 | 0.62 |
| MACD | 0.23 | 0.19 |
| Stochastic Oscillator | 69.52 | 85.45 |
The Beachbody Co Inc is a fitness and nutrition company providing fitness, nutrition, and stress-reducing programs to its customers. a results-oriented company at the intersection of wellness, technology, and media. The company developed one of the original fitness digital streaming platforms with an extensive library of content containing streaming programs and streaming videos. Company products include Digital Subscriptions, Nutritional Products, and Connected Fitness Products, where the majority of revenue is from Digital Subscriptions. The Company has one operating and reporting segment. Geographically operates in the USA and the rest of the world, with maximum revenue from the United States.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.